View source for BCX-1777

== BCX-1777 ==

'''BCX-1777''' (pronunciation: B-C-X-1777), also known as '''forodesine''', is a [[transition state analogue]] inhibitor that has been used in the experimental treatment of [[T-cell]] acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL). 

=== Etymology ===

The name '''BCX-1777''' is derived from the code assigned to it during its development phase by BioCryst Pharmaceuticals. The alternative name, '''forodesine''', is a combination of the Latin word 'foro', meaning 'to bore through', and 'desine', meaning 'to cease', reflecting its function as a drug designed to halt the progression of certain types of cancer.

=== Mechanism of Action ===

'''BCX-1777''' works by inhibiting the enzyme [[purine nucleoside phosphorylase]] (PNP), which plays a crucial role in the survival of [[T-cells]]. By inhibiting PNP, BCX-1777 disrupts the metabolic processes of the T-cells, leading to their death and thus slowing the progression of T-cell related cancers.

=== Related Terms ===

* [[Transition state analogue]]
* [[T-cell]]
* [[Acute lymphoblastic leukemia]]
* [[Cutaneous T-cell lymphoma]]
* [[Purine nucleoside phosphorylase]]
* [[BioCryst Pharmaceuticals]]

[[Category:Pharmaceuticals]]
[[Category:Oncology]]
[[Category:Medical Dictionary]]

{{dictionary-stub}}